Marc Odrich
Keine laufenden Positionen mehr
Vermögen: 2 Mio $ am 30.04.2024
Profil
Marc Odrich is currently the Chief Medical Officer & Director at TearSolutions, Inc., the Director at CXL Ophthalmics LLC, the Chief Medical Officer at LENZ Therapeutics, Inc., and an Associate Professor at the University of Virginia.
He previously worked as the Medical Director at VISX, Inc. Dr. Odrich holds a doctorate degree from Columbia University College of Physicians & Surgeons.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0,39% | 21.03.2024 | 99 599 ( 0,39% ) | 2 Mio $ | 30.04.2024 |
Aktive Positionen von Marc Odrich
| Unternehmen | Position | Beginn |
|---|---|---|
TearSolutions, Inc.
 TearSolutions, Inc. BiotechnologyHealth Technology TearSolutions, Inc. develops natural tear generation therapy for dry eyes. The firm's platform technology focuses on the tear protein 'lacritin'? and the proprietary drug 'Lacripep'?. The company was founded by Mark B. Logan, and Gordon W. Laurie in 2013 and is headquartered in Charlottesville, VA. | Corporate Officer/Principal | - |
CXL Ophthalmics LLC
 CXL Ophthalmics LLC Medical/Nursing ServicesHealth Services CXL Ophthalmics LLC develops a treatment for eyecare. The company is based in Encinitas, CA. The CEO of the company is Michael D. Webb. | Direktor/Vorstandsmitglied | - |
| University of Virginia | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Marc Odrich
| Unternehmen | Position | Ende |
|---|---|---|
| VISX, Inc. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Marc Odrich
| Columbia University College of Physicians & Surgeons | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
TearSolutions, Inc.
TearSolutions, Inc. BiotechnologyHealth Technology TearSolutions, Inc. develops natural tear generation therapy for dry eyes. The firm's platform technology focuses on the tear protein 'lacritin'? and the proprietary drug 'Lacripep'?. The company was founded by Mark B. Logan, and Gordon W. Laurie in 2013 and is headquartered in Charlottesville, VA. | Health Technology |
| VISX, Inc. | |
CXL Ophthalmics LLC
CXL Ophthalmics LLC Medical/Nursing ServicesHealth Services CXL Ophthalmics LLC develops a treatment for eyecare. The company is based in Encinitas, CA. The CEO of the company is Michael D. Webb. | Health Services |